<DOC>
	<DOCNO>NCT01203514</DOCNO>
	<brief_summary>This study test safety efficacy transfuse erythropoietin ( Epo ) iron infant &lt; 1,250g birth weight . For infant 401-1,000g birth weight , test whether early erythropoietin ( Epo ) iron therapy would decrease number transfusion receive . For infant 1,001-1,250g birth weight , test whether early erythropoietin ( Epo ) iron therapy would decrease percentage infant receive transfusion .</brief_summary>
	<brief_title>The Effects Erythropoietin ( EPO ) Transfusion Requirements Very Low Birth Weight Infants</brief_title>
	<detailed_description>Critically ill preterm infant experience first 1-2 week birth daily blood loss may equal 5-10 % total blood volume . Such loss associate anemia typically result multiple erythrocyte transfusion . This iatrogenic anemia commonly follow anemia prematurity , prompt additional transfusion . This study test safety efficacy transfuse erythropoietin ( Epo ) iron infant &lt; 1,250g birth weight . For infant 401-1,000g birth weight ( Trial 1 ) , test whether early erythropoietin ( Epo ) iron therapy would decrease number transfusion receive . For infant 1,001-1,250g birth weight ( Trial 2 ) , test whether early erythropoietin ( Epo ) iron therapy would decrease percentage infant receive transfusion . Therapy initiate day life 4 continue 35th postmenstrual week . Infants randomize receive either Epo iron therapy sham procedure . Treated infant receive 400 U/kg Epo 3 time weekly weekly intravenous infusion 5 mg/kg iron dextran enteral intake 60 mL/kg/d . Infants placebo/control group receive sham subcutaneous injection intravenous access available . Complete blood reticulocyte count measure weekly , ferritin concentration measure monthly . Transfusions administer accord protocol . Infants receive transfusion solely replace blood lose phlebotomy . Infants meet transfusion criterion receive transfusion 15 mL/kg pack red blood cell ( PRBC ) hematocrit &gt; 25 % 20 mL/kg PRBC hematocrit &lt; =25 % . Blood loss transfusion data record . Trial 2 terminate enrollment 118 infant Data Safety Monitoring Committee review final result Trial 1 preliminary result Trial 2 . On basis data , Committee conclude statistically unlikely Trial 2 would demonstrate significant decrease percentage infant would receive transfusion study .</detailed_description>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Anemia , Neonatal</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Infants birth weight 40101250g , &lt; 32 week ' gestation , 2496 hour old time study entry Likely survive &gt; 72 hour Informed consent parent guardian . Major congenital anomaly A positive direct antiglobulin test Evidence coagulopathy Clinical seizure Systolic blood pressure &gt; 100 mm Hg ( absence pressor support ) Absolute neutrophil count ( ANC ) &lt; =500/microL</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>96 Days</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>NICHD Neonatal Research Network</keyword>
	<keyword>Extremely Low Birth Weight ( ELBW )</keyword>
	<keyword>Prematurity</keyword>
	<keyword>Erythrocyte transfusion</keyword>
	<keyword>Erythropoietin ( Epo )</keyword>
	<keyword>Blood loss</keyword>
	<keyword>Phlebotomy</keyword>
</DOC>